We need a temporary moratorium on using gene editing to create babies
By Paul Knoepfler,
STAT
| 12. 03. 2018
The rationales for human germline editing don’t make much sense to me. They consist of invoking rare or even hypothetical scenarios where CRISPR might serve some purpose that cannot be achieved by already proven and safe embryo screening methods such as pre-implantation genetic diagnosis.
On a cold, drizzly night almost three years ago, I stood inside the nearly deserted Lincoln Memorial in Washington, D.C., I was in town to attend the first International Summit on Human Gene Editing organized by the National Academy of Sciences and the National Academy of Medicine. After a day of intense talks at the meeting, I had gone for a long walk and found myself looking up at Big Abe. A big question was on my mind: Would the organizers of the meeting call for a moratorium on using CRISPR to make gene-edited babies, as I hoped they would?
They didn’t.
When I learned of that decision, my feeling was that someone would report the creation of the first “CRISPR baby” within the next few years. That might happen even with a moratorium, but the odds had just increased substantially.
Since then, there have been similar meetings around the world about human germline gene editing — editing eggs, sperm, and embryos that are then used to make people — along with official reports from committees. None called for a...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...